Cybin Reports Strong Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. has reported strong institutional demand in its second-quarter 2025 results while advancing multiple late-stage clinical programs for mental health treatments, positioning the company for key 2026 data readouts that could significantly impact neuropsychiatry treatment options.
Cybin Inc. reported second-quarter 2025 results and recent business highlights, noting strong institutional demand for its completed financing. Interim CEO Eric So stated this reinforces confidence in the company's science, differentiated therapeutic candidates and ability to execute as it advances toward key 2026 data readouts. The company completed enrollment in its Phase 2 CYB004 study for generalized anxiety disorder and continued progressing CYB003 through the Phase 3 APPROACH and EXTEND trials.
The company secured additional global regulatory approvals to initiate the EMBRACE Phase 3 study for adjunctive major depressive disorder treatment. Cybin expanded its intellectual property estate to more than 100 granted patents and over 250 pending applications worldwide. The Board formed a committee to conduct a CEO search to guide the next stage of growth and late-stage clinical development. Additional information about the company's progress is available in their newsroom at https://ibn.fm/CYBN.
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising class-leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients.
The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule is in a Phase 2 study for generalized anxiety disorder. The Company also maintains a research pipeline of investigational, 5-HT-receptor focused compounds. Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland.